PATENT CLAIM ANALYSIS

Application Number: 16069546
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "001890"]

Abstract:
Radiolabeled compounds which are erlotinib analogs that feature a radioactive halogen and processes of preparing same are disclosed. Uses of these radiolabeled compounds in radioimaging, for identifying and monitoring a level, distribution and/or mutational status of deregulated EGFR, and/or in radiotherapy, are also disclosed.

Claim (Index 68):
The method of  claim 67 , wherein said proliferative disease or disorder is selected from the group consisting of non-small cell lung cancer (NSCLC), pancreatic cancer, head and neck squamous cell carcinoma (HNSCC), brain cancer, breast cancer, esophageal cancer, gastric cancer, renal cancer, cervical cancer, ovarian cancer, hepatocellular cancer, malignant glioma, prostate cancer, colorectal cancer (CRC), bladder cancer, gynecological cancer, thyroid cancer and lymphoma.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 95.0
- Lexical Diversity: 1.38889
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11714760', '10659747', '12449129', '14023681', '12631116']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5136181117935382
- 35 USC 102 Novelty (BERT): 0.5207427095132697
- Combined Prediction Score: 0.5143305715655114
- Mean Citation Score: 235.110082
- Max Citation Score: 283.49173
- Similarity Product: 171.12068459263088

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test